BUSINESS

• Kyowa Kirin Begins Global KRN23 PIII for Pediatric X-Linked Hypophosphatemia
  October 28, 2016

• Sumitomo Dainippon’s Half-Year Revenue Dips on Price Cut, Currency
  October 28, 2016

• Sumitomo Dainippon to Venture into Authorized Generic Arena
  October 28, 2016

• Public “IP Platforms” Necessary for Startups: IPSN President
  October 28, 2016

• Daiichi Sankyo Gets US Commercialization Rights on 2 Abuse-Deterrent Opioids
  October 27, 2016

• Patritumab Joins I-SPY 2 Breast Cancer Program in US: Daiichi Sankyo
  October 27, 2016

• Switching Over to Biologics Should Be Considered at Early Stage in Serious Cases of Psoriasis: Dermatologist
  October 27, 2016

• AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
  October 26, 2016

• Wholesalers Hails Gilead Ambition to Unearth More Hep C Patients through Collaboration
  October 26, 2016

• Mitsubishi Tanabe Lifts Earnings Outlook on Simponi, Vaccines
  October 26, 2016

• Prof. Yamanaka Eager to Bridge Valley of Death through Takeda Collaboration
  October 25, 2016

• Astellas Wins Xtandi Label Update in US for PFS Extension
  October 25, 2016

• Sunovion Completes Acquisition of Cynapsus
  October 25, 2016

• Shionogi Ups Earnings Forecast for April-September
  October 25, 2016

• Ono Files Patent Infringement Suit over Keytruda
  October 25, 2016

• Nihon Generic Takes Over 3 Brands from MSD
  October 24, 2016

• Prasugrel Disappoints in PIII Study for Ischemic Cerebrovascular Disease
  October 24, 2016

• 295 Staffers Applied for Voluntary Redundancy: Sumitomo Dainippon
  October 24, 2016

• Daiichi Sankyo Stops Patient Enrollment for Pexidartinib PIII, but Continues Study
  October 24, 2016

• Oncolys, DNA Chip Research Team Up to Study Potential of TelomeScan as Companion Diagnostic for CRPC
  October 24, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 443
• 444
• 445
• 446
• 447
• 448
• 449
• 450
• 451
• …
• Next ›
• 最終 »